System architecture in quantum computing – history repeating itself?

No items found.
​
December 24, 2025

A practical quantum computer is closer to reality than ever before. Massive investments of time and resources are accelerating research in quantum computing, bringing us steadily nearer to viable implementations. Optimistic projections suggest that a usable quantum computer (QC) could emerge within five years ​[1]​, while one capable of breaking conventional cryptosystems such as RSA and Diffie-Hellman may be around a decade away ​[2]​. In this article, we examine the current state and challenges of quantum hardware, explore the evolution of system architectures for QCs, and identify areas where intellectual property could play a pivotal role—revealing how history may be poised to repeat itself.

Where quantum hardware poses challenges, system architecture unlocks opportunities

The discussion around quantum hardware has primarily revolved around physical implementations of qubits. This is the fundamental building block of quantum computing, the quantum counterpart to a classical bit. Unlike a classical bit, which can only take one of two discrete values (0 or 1), a qubit exists in a continuous state space, demonstrating phenomena such as superposition and entanglement ​[3]​. In principle, any physical system with two distinct quantum states can serve as a qubit, though some implementations are more practical than others. Today, the most widely adopted approaches include superconducting qubits (notably linked to the 2025 Nobel Prize in Physics as discussed in an earlier article), trapped-ion qubits, and photonic qubits. This remains an active research area with significant investment from major technology companies such as IBM, Intel, and Google. Despite progress, substantial challenges persist—particularly in scaling systems, achieving reliable read/write operations, and performing computations before quantum states degrade due to noise and decoherence ​[3]​.

From a historical perspective, quantum computing today is roughly at the stage classical computing was in the mid-1930s. The first patent for a transistor, a fundamental hardware component in classical computing, claims priority in 1925 and was invented by J.E. Lilienfeld (US Patent 1745175 A). However, it was not until 1948 that Bell Labs produced the first practical semiconductor transistor, enabling commercial applications. Quantum computing currently sits between the initial demonstration of a physical qubit and the onset of large-scale commercialisation—the modern equivalent of 1935. Later, in the 1960s, the concept of an instruction set architecture (ISA) was introduced in classical computing, which provided a translation layer between hardware logic and low-level software. This sparked a debate: should ISAs remain minimal, leaving complexity to software (RISC), or should hardware implement complex instructions for performance (CISC)? Both approaches ultimately succeeded. RISC architectures such as ARM dominate mobile devices, while CISC architectures like Intel’s x86 power desktops ​[4]​. A similar discussion is likely to emerge in quantum computing, and this is an area where intellectual property could once again play a significant role.

A quantum ISA

Unlike classical computing, where ISAs emerged decades after the first hardware breakthroughs, ISA development can already be found in quantum computing. One example is the recently granted US patent 12386604B2, which discloses a quantum ISA by research scientist Anastasiia Butko at Lawrence Berkeley National Laboratory. In the patent, a key distinction is highlighted: classical architectures rely primarily on a single type of device, arithmetic logic unit (ALU), to perform various operations, whereas quantum architectures employ a variety of quantum gates applied directly to qubits ​[5]​. Consequently, the design question shifts from which operations to implement in an ALU to which quantum gates should be natively supported on a quantum chip.

This raises a familiar debate. In quantum computing, a universal set of gates is one to which any quantum computation can be reduced. While it is logical for a quantum processor to have a universal set, whether that set should be minimal remains an open question. The cited patent takes a clear position, proposing that “a quantum device exposes a minimal set of native gates that constitute a universal set” and extending a reduced instruction set (RISC) to a quantum ISA ​[5]​.

The landscape is ripe for innovation

A brief survey reveals only two other patent families directly addressing quantum ISAs, one of which also adopts a RISC-based approach. With just three families identified, this appears to be an area ripe for innovation. Could a CISC-based quantum ISA offer advantages over RISC-based designs, or might both coexist as in classical computing? The architecture that achieves large-scale adoption will likely create licensing opportunities, similar to the dominance of x86 in classical systems.

In summary, quantum computing development is progressing on multiple fronts. While hardware research continues to grapple with the challenges of fundamental physics, system architecture is already gaining traction. The field remains open for innovation, and as scalable quantum computers approach, we may see a quantum version of the RISC versus CISC debate. When that time comes, EIP stands ready with its Quantiphy offering to provide strategic guidance and expertise in intellectual property for quantum technologies.

​​References

​[1]  

​D. Milmo, “Google hails breakthrough as quantum computer surpasses ability of supercomputers,” The Guardian, 22 October 2025. [Online]. Available: https://www.theguardian.com/technology/2025/oct/22/google-hails-breakthrough-as-quantum-computer-surpasses-ability-of-supercomputers. [Accessed 4 December 2025].

​[2]  

​P. Asplund, “Forskar om att framtidssäkra internet,” KTH, 30 October 2024. [Online]. Available: https://www.kth.se/om/nyheter/centrala-nyheter/forskar-om-att-framtidssakra-internet-1.1366813. [Accessed 4 December 2025].

​[3]  

​Wikipedia contributors, “Quantum computing,” Wikipedia, The Free Encyclopedia, 2025.

​[4]  

​S. Sinofsky, “RISC v CISC: An Age Old Debate,” Medium, 3 May 2022. [Online]. Available: https://medium.learningbyshipping.com/risc-v-cisc-an-age-old-debate-79d859668d35. [Accessed 5 December 2025].

​[5]  

​A. Butko, “QUANTUM INSTRUCTION SET ARCHITECTURE”. US Patent 12386604 B2, 12 August 2025.

‍

‍

The Latest Thought Leadership pieces in the Content Hub

Quantum Sensors: What are they and why do they matter to healthcare?
May 19, 2025
The UN says we are in a year of quantum, celebrating 100 years since the development of quantum mechanics. While quantum computing is often the main talking point, the other areas of quantum tech,...
Building a Resilient Quantum Patent Portfolio: Winning the Race to File First
May 29, 2025
A key question for those working in a fast-paced and complex industry such as quantum technology is when to patent any technological developments.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​